IngentaConnect Search Results

Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review

Authors: Izzo, Angelo A.; Ernst, Edzard

Source: Drugs, Volume 69, Number 13, 10 September 2009 , pp. 1777-1798(22)

Maximal Inhibition of Intestinal First-Pass Metabolism as a Pragmatic Indicator of Intestinal Contribution to the Drug-Drug Interactions for CYP3A4 Cleared Drugs

Authors: Galetin, Aleksandra; Hinton, Laura K.; Burt, Howard; Obach, R. S.; Houston, J. B.r.i.a.n.

Source: Current Drug Metabolism, Volume 8, Number 7, October 2007 , pp. 685-693(9)

Publisher: Bentham Science Publishers

General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs

Authors: Ohno, Yoshiyuki; Hisaka, Akihiro; Suzuki, Hiroshi

Source: Clinical Pharmacokinetics, Volume 46, Number 8, 2007 , pp. 681-696(16)

Publisher: Adis International

Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of Liver

Authors: Barter, Zoe E.; Bayliss, Martin K.; Beaune, Philip H.; Boobis, Alan R.; Carlile, David J.; Edwards, Robert J.; Brian Houston, J.; Lake, Brian G.; Lipscomb, John C.; Pelkonen, Olavi R.; Tucke, Geoffrey T.; Rostami-Hodjegan, Amin

Source: Current Drug Metabolism, Volume 8, Number 1, January 2007 , pp. 33-45(13)

Publisher: Bentham Science Publishers

Drug-Herb Interactions: Eliminating Toxicity with Hard Drug Design

Authors: Yang, Xiao-Xia; Hu, Ze-Ping; Duan, Wei; Zhu, Yi-Zhun; Zhou, Shu-Feng

Source: Current Pharmaceutical Design, Volume 12, Number 35, December 2006 , pp. 4649-4664(16)

Publisher: Bentham Science Publishers

Prediction of metabolic drug clearance in humans: In vitro-in vivo extrapolation vs allometric scaling

Authors: Shiran, M. R.; Proctor, N. J.; Howgate, E. M.; Rowland-Yeo, K.; Tucker, G. T.; Rostami-Hodjegan, A.

Source: Xenobiotica, Volume 36, Number 7, July 2006 , pp. 567-580(14)

Publisher: Informa Healthcare

Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences

Authors: Inoue†, S.; Howgate, E. M.; Rowland-Yeo, K.; Shimada, T.; Yamazaki, H.; Tucker, G. T.; Rostami-Hodjegan, A.

Source: Xenobiotica, Volume 36, Number 6, June 2006 , pp. 499-513(15)

Publisher: Informa Healthcare

Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans

Authors: Rawden, H. C.; Carlile, D. J.; Tindall, A.; Hallifax, D.; Galetin, A.; Ito, K.; Houston, J. B.

Source: Xenobiotica, Volume 35, Number 6, Number 6/June 2005 , pp. 603-625(23)

Publisher: Informa Healthcare

Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective

Authors: Desai H.D.; Seabolt J.; Jann M.W.

Source: CNS Drugs, Volume 15, Number 6, 2001 , pp. 469-494(26)

Publisher: Adis International

The biological basis and pharmacological treatment of anxiety: do the elderly differ?

Author: Leonard B.E.

Source: FEBS Letters, Volume 5, Number 3, September 1995 , pp. 247-247(1)

Publisher: Elsevier

Clinical Pharmacokinetics of Reboxetine, a Selective Norepinephrine Reuptake Inhibitor for the Treatment of Patients with Depression

Author: Fleishaker J.C.

Source: Clinical Pharmacokinetics, Volume 39, Number 6, December 2000 , pp. 413-427(15)

Publisher: Adis International

Pharmacokinetics of Haloperidol: An Update

Authors: Kudo S.; Ishizaki T.

Source: Clinical Pharmacokinetics, Volume 37, Number 6, December 1999 , pp. 435-456(22)

Publisher: Adis International

Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug

Authors: Mahmood I.; Sahajwalla C.

Source: Clinical Pharmacokinetics, Volume 36, Number 4, April 1999 , pp. 277-287(11)

Publisher: Adis International

Decreased clearance by ketoconazole has greater clinical consequences for triazolam than for alprazolam

Source: Reactions, Volume 1, Number 725, 1998 , pp. 5-5(1)

Publisher: Adis International

Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents

Authors: Hsu A.; Granneman G.R.; Bertz R.J.

Source: Clinical Pharmacokinetics, Volume 35, Number 4, October 1998 , pp. 275-291(17)

Publisher: Adis International

Effect of Carbamazepine on the Single Oral Dose Pharmacokinetics of Alprazolam - In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism

Authors: Furukori M.D.; Otani M.D.; Yasui M.D.; Kondo M.D.; Kaneko M.D.; Shimoyama B.S.; Ohkubo P.D.; Nagasaki B.S.; Sugawara P.D.

Source: Neuropsychopharmacology, Volume 18, Number 5, May 1998 , pp. 364-369(6)

Publisher: Elsevier

In Vitro Approaches to Predicting Drug Interactions In Vivo - Potent inhibition by fluvoxamine

Authors: von Moltke L.L.; Greenblatt D.J.; Schmider J.; Wright C.E.; Harmatz J.S.; Shader R.I.

Source: Biochemical Pharmacology, Volume 55, Number 2, 15 January 1998 , pp. 113-122(10)

Publisher: Elsevier

Nonlinear Mixed Effects Modeling of Single Dose and Multiple Dose Data for an Immediate Release (IR) and a Controlled Release (CR) Dosage Form of Alprazolam

Authors: Hossain M.; Wright E.; Baweja R.; Ludden T.; Miller R.

Source: Pharmaceutical Research, Volume 14, Number 3, March 1997 , pp. 309-315(7)

Publisher: Springer

The biological basis and pharmacological treatment of anxiety: do the elderly differ?

Author: Leonard B.E.

Source: European Neuropsychopharmacology, Volume 5, Number 3, September 1995 , pp. 247-247(1)

Publisher: Elsevier